当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2024-05-08 , DOI: 10.1111/apt.18037 Toshifumi Tada 1 , Takashi Kumada 2 , Atsushi Hiraoka 3 , Masashi Hirooka 4 , Kazuya Kariyama 5 , Joji Tani 6 , Masanori Atsukawa 7 , Koichi Takaguchi 8 , Ei Itobayashi 9 , Shinya Fukunishi 10 , Hiroki Nishikawa 11 , Kunihiko Tsuji 12 , Toru Ishikawa 13 , Kazuto Tajiri 14 , Yuichi Koshiyama 15 , Hidenori Toyoda 15 , Chikara Ogawa 16 , Takeshi Hatanaka 17 , Satoru Kakizaki 18 , Kazuhito Kawata 19 , Hideko Ohama 20 , Fujimasa Tada 3 , Kazuhiro Nouso 5 , Asahiro Morishita 6 , Akemi Tsutsui 8 , Takuya Nagano 8 , Norio Itokawa 7 , Tomomi Okubo 7 , Taeang Arai 7 , Takashi Nishimura 10 , Michitaka Imai 13 , Hisashi Kosaka 21 , Atsushi Naganuma 22 , Tomomitsu Matono 23 , Tomoko Aoki 24 , Hidekatsu Kuroda 25 , Yutaka Yata 26 , Yohei Koizumi 4 , Shinichiro Nakamura 1 , Hirayuki Enomoto 10 , Masaki Kaibori 21 , Yoichi Hiasa 4 , Masatoshi Kudo 24 , ,
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2024-05-08 , DOI: 10.1111/apt.18037 Toshifumi Tada 1 , Takashi Kumada 2 , Atsushi Hiraoka 3 , Masashi Hirooka 4 , Kazuya Kariyama 5 , Joji Tani 6 , Masanori Atsukawa 7 , Koichi Takaguchi 8 , Ei Itobayashi 9 , Shinya Fukunishi 10 , Hiroki Nishikawa 11 , Kunihiko Tsuji 12 , Toru Ishikawa 13 , Kazuto Tajiri 14 , Yuichi Koshiyama 15 , Hidenori Toyoda 15 , Chikara Ogawa 16 , Takeshi Hatanaka 17 , Satoru Kakizaki 18 , Kazuhito Kawata 19 , Hideko Ohama 20 , Fujimasa Tada 3 , Kazuhiro Nouso 5 , Asahiro Morishita 6 , Akemi Tsutsui 8 , Takuya Nagano 8 , Norio Itokawa 7 , Tomomi Okubo 7 , Taeang Arai 7 , Takashi Nishimura 10 , Michitaka Imai 13 , Hisashi Kosaka 21 , Atsushi Naganuma 22 , Tomomitsu Matono 23 , Tomoko Aoki 24 , Hidekatsu Kuroda 25 , Yutaka Yata 26 , Yohei Koizumi 4 , Shinichiro Nakamura 1 , Hirayuki Enomoto 10 , Masaki Kaibori 21 , Yoichi Hiasa 4 , Masatoshi Kudo 24 , ,
Affiliation
|
Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC).
中文翻译：
在现实临床实践中，符合或不符合 3 期 IMbrave150 试验纳入标准的肝细胞癌患者接受 atezolizumab 加贝伐珠单抗治疗的结果
Atezolizumab 加贝伐单抗 (Atezo/Bev) 经常被选为肝细胞癌 (HCC) 的主要全身治疗。
更新日期：2024-05-08
中文翻译：
在现实临床实践中，符合或不符合 3 期 IMbrave150 试验纳入标准的肝细胞癌患者接受 atezolizumab 加贝伐珠单抗治疗的结果
Atezolizumab 加贝伐单抗 (Atezo/Bev) 经常被选为肝细胞癌 (HCC) 的主要全身治疗。
京公网安备 11010802027423号